| Literature DB >> 35241152 |
Emmanuel Sopbué Fondjo1, Abdou Salamou Njoya2, Jean-de-Dieu Tamokou3, Giscard Doungmo4, Bruno Ndjakou Lenta5, Peter F W Simon6, Apollinaire Tsopmo7, Jules-Roger Kuiate3.
Abstract
A new diazo derivative of a pyrrolidine-2,5-dione (8) fused at position-3,4 to a dibenzobarrelene backbone has been prepared by coupling the previously reported N-arylsuccinimid (5) precursor with aryldiazonium ion of aniline. The initial step of the reaction involved the preparation of the intermediate 9,10-dihydro-9,10-ethanoanthracene-11,12-dicarboxylic anhydride (3) through [4 + 2]-cycloaddition between anthracene and maleic anhydride in refluxing xylene which was then condensed with para-aminophenol to give compound 5. Compounds 5 and 8 were characterized by their physical, elemental, and spectroscopic data. 2D-NMR (COSY, HSQC, and HMBC) techniques were used to confirm the structure of compound 5. Compounds 5 (MIC = 32-128 μg/mL) and 8 (MIC = 16-256 μg/mL) along with the precursor 3 (MIC = 64-128 μg/mL) displayed moderate to low antimicrobial activities against selected bacterial and fungal species when compared with those of nystatin (MIC = 0.50-2 μg/mL) and ciprofloxacin (MIC = 0.50-16 μg/mL) used as reference drugs.Entities:
Keywords: Anti-microbial activities; Azo compound; Dibenzobarrelene; N-arylsuccinimid; Phenols; Pyrrolidine
Year: 2022 PMID: 35241152 PMCID: PMC8895586 DOI: 10.1186/s13065-022-00801-5
Source DB: PubMed Journal: BMC Chem ISSN: 2661-801X
Scheme 1Structure of pyrrolidine and their derivatives
Scheme 2Basic structure of dibenzobarrelene
Scheme 3Reactions sequences to compound 5
Scheme 4Reactions sequences to compound 8
Scheme 5Some important fragments of compound 8 observed in the ESI+-mode MS
Fig. 1Ex situ PXRD pattern (Cu Kα1 radiation) of XRD of compound 5 and 8
Fig. 2Optimized 3D view of compound 8. The structure was drawn with the program ACD/3D viewer (freeware) of ACD/Labs
Antimicrobial activity (MIC, MBC and MFC in µg/mL) of synthesized compounds as well as reference antimicrobial drugs
| Compounds | Inhibition parameters | |||||||
|---|---|---|---|---|---|---|---|---|
| MIC | 16 | 64 | 32 | 64 | 256 | 128 | 64 | |
| MBC or MFC | 32 | 128 | 64 | > 256 | > 256 | > 256 | 128 | |
| MBC or MFC /MIC | 2 | 2 | 2 | / | / | / | 2 | |
| MIC | 32 | 64 | 64 | 128 | 128 | 64 | 64 | |
| MBC or MFC | 32 | 128 | 128 | > 256 | > 256 | > 256 | > 256 | |
| MBC or MFC /MIC | 1 | 2 | 2 | / | / | / | / | |
| MIC | 64 | 64 | 64 | 128 | 128 | 128 | 128 | |
| MBC or MFC | 128 | 128 | 128 | > 256 | > 256 | 256 | 256 | |
| MBC or MFC /MIC | 2 | 2 | 2 | / | / | 2 | 2 | |
| Reference drugs* | MIC | 0.50 | 16 | 8 | 16 | 2 | 0.50 | 1 |
| MBC or MFC | 0.50 | 16 | 8 | 16 | 2 | 0.50 | 1 | |
| MBC or MFC /MIC | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
/ not determined, MIC Minimum Inhibitory Concentration, MBC Minimum Bactericidal Concentration, MFC Minimum Fungicidal Concentration
*Nystatin for yeasts and ciprofloxacin for bacteria were tested together with compounds 3, 5 and 8